Losartan for Adolescent Girls (Ages 12 to 17): Off-Label Use, Dosing, and What Parents Need to Know

What Losartan Is and Why Adolescent Girls Are Prescribed It

Losartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the AT1 receptor, reducing vasoconstriction and aldosterone-driven sodium retention. The FDA label for losartan approves it for hypertension in pediatric patients aged 6 and older, making the drug "on-label" for a hypertensive 14-year-old girl. Several other clinical scenarios that arise specifically in adolescent girls, however, are genuinely off-label.

Understanding the distinction matters because off-label use means the dosing, safety, and efficacy data are thinner. Girls have historically been under-represented in pediatric cardiovascular trials, and almost no trial has examined sex-specific pharmacokinetics of losartan in adolescents directly. Where female-specific data exist, they are noted below. Where they are extrapolated from adult women or from mixed-sex pediatric cohorts, that is stated plainly.

Why Adolescence Is a Distinct Pharmacological Window

Puberty reshapes body composition, kidney function, and hormonal milieu in ways that affect how drugs behave. Estrogen rises sharply in girls between ages 11 and 15, and estrogen influences the renin-angiotensin-aldosterone system (RAAS), the exact system losartan targets. Adult women tend to have lower baseline renin activity than men of the same age, a difference that emerges during puberty, though direct pharmacokinetic studies of losartan in adolescent girls specifically are lacking. Clinicians often extrapolate from adult female data, which itself shows that women reach slightly higher peak plasma concentrations of losartan's active metabolite (EXP3174) than men at equivalent weight-adjusted doses.

Blood pressure also follows a sex-specific developmental arc. Girls' systolic blood pressure rises steeply between ages 8 and 13, then plateaus, while boys' continues climbing through mid-adolescence. Normative blood pressure tables from the American Academy of Pediatrics 2017 Clinical Practice Guideline are therefore sex- and age-specific, meaning a reading that is hypertensive in a 13-year-old girl may be borderline-normal for a boy the same age.

On-Label vs. Off-Label Uses in Adolescent Girls: A Clear Map

Losartan's FDA approval for pediatric hypertension covers a girl aged 12 to 17 with elevated blood pressure from any cause, so long as oral medication is appropriate. That is on-label territory. The following uses are off-label in this age group.

Marfan Syndrome and Aortic Root Protection

Marfan syndrome affects connective tissue through FBN1 mutations. In teenage girls with Marfan syndrome, aortic root dilation is a life-threatening concern that becomes especially urgent in the context of future pregnancy. The PEDIATRIC Heart Network's GenTAC trial and the COMPARE trial compared losartan to atenolol in Marfan patients and found losartan non-inferior for slowing aortic root growth, with some analyses suggesting benefit in younger patients. Losartan is now widely used for this indication in adolescents despite formal approval applying only to hypertension.

The female-specific issue here is substantial: girls with Marfan syndrome who reach reproductive age face a 30% or greater risk of aortic dissection during pregnancy, making early counseling about contraception and pregnancy planning a clinical priority that begins in adolescence, not adulthood.

PCOS-Related Hypertension and Insulin Resistance

Polycystic ovary syndrome (PCOS) affects an estimated 6 to 12% of reproductive-age women and commonly emerges at or just after puberty. Adolescent girls with PCOS frequently present with hypertension, hyperinsulinemia, and early metabolic dysfunction. Some clinicians prescribe ARBs like losartan when hypertension accompanies PCOS, partly because the RAAS is overactive in insulin-resistant states and partly because ARBs have a neutral-to-favorable metabolic profile compared to beta-blockers.

This use is off-label. No randomized controlled trial has specifically examined losartan for blood pressure control in adolescent girls with PCOS. Adult data from the RENAAL trial examined losartan in diabetic nephropathy, a metabolic context that overlaps mechanistically, but those were adults, not teens, and the sex breakdown was not separately analyzed for the adolescent subset.

Proteinuric Chronic Kidney Disease

Girls with chronic kidney disease (CKD) and significant proteinuria may receive losartan for its nephroprotective effects, which are mediated through reduced intraglomerular pressure and direct anti-fibrotic actions of angiotensin blockade. The ESCAPE trial showed that intensified blood pressure control in pediatric CKD slows progression, and ARBs are commonly selected agents. This remains off-label for the specific kidney diagnoses involved even when the patient is in the approved age range for hypertension.

Dosing Losartan in Adolescent Girls

The FDA-approved starting dose for pediatric hypertension is 0.7 mg/kg once daily, with a maximum of 50 mg/day as the starting dose and up to 100 mg/day as needed. For a 14-year-old girl weighing 55 kg, that translates to approximately 38.5 mg/day, typically rounded to the available tablet strength of 25 mg or 50 mg.

Weight-Based vs. Fixed Dosing

In practice, once a girl is above roughly 40 kg, many clinicians transition to adult-style fixed dosing (25 mg, 50 mg, or 100 mg once daily) because weight-based calculations at higher body weights produce doses that match standard tablet strengths anyway. Girls with obesity, which is increasingly common in the adolescent PCOS population, may have altered volume of distribution and renal clearance, though no losartan-specific pharmacokinetic data in adolescent girls with obesity have been published as of this writing.

Renal Adjustment

Losartan dose reduction is required in adults with a GFR below 30 mL/min/1.73 m², and by extension in adolescents. Girls with CKD being treated for proteinuria should have GFR estimated at baseline and monitored at least every 3 months.

The Suspension Formulation

For younger adolescents or those who cannot swallow tablets, a 2.5 mg/mL oral suspension can be compounded per the FDA label. The suspension is less reliably absorbed than tablets in some studies, so girls transitioning from suspension to tablet form should have blood pressure rechecked within two to four weeks.

Sex-Specific Physiology: How the Menstrual Cycle Affects Blood Pressure and Drug Response

This section applies directly to adolescent girls once they have established menstrual cycles, typically by ages 13 to 15.

Blood pressure varies across the menstrual cycle. Luteal-phase progesterone has mild natriuretic and vasodilatory effects, which can lower blood pressure slightly in the two weeks before menstruation. Conversely, some girls experience premenstrual fluid retention and a transient blood pressure rise. For a girl being titrated on losartan, blood pressure readings taken at different cycle phases may look inconsistent, making it worth timing clinic measurements to the same phase of the cycle where possible, ideally days 2 to 5 of the follicular phase, when hormonal background is most stable.

Cycle irregularity is common in girls with PCOS and in girls within the first two years after menarche (the "anovulatory window"). Up to 85% of cycles in the first year after menarche are anovulatory, which flattens the luteal progesterone effect and may make blood pressure more stable across the month. Clinicians should factor this in when evaluating treatment response.

Dysmenorrhea (painful periods) leads some adolescent girls to regularly use NSAIDs like ibuprofen. NSAIDs blunt the antihypertensive effect of ARBs and can acutely impair renal function when combined with losartan, a combination the FDA label explicitly warns against. Girls taking losartan should be counseled to use acetaminophen preferentially for period pain.

Pregnancy and Lactation: The Non-Negotiable Safety Warning

Losartan is contraindicated in pregnancy. This applies to any sexually active adolescent girl.

This is not a nuanced, weigh-the-risks conversation. When taken during the second or third trimester, drugs that block the RAAS, ACE inhibitors and ARBs alike, cause fetal renal tubular dysplasia, oligohydramnios, neonatal renal failure, and skull hypoplasia, with a documented fetal death rate. The FDA withdrew the former "Category C for first trimester, Category D for second/third trimester" framing in 2015 when it moved to narrative labeling, but the underlying data have not changed. The 2022 ACOG Practice Bulletin on Chronic Hypertension in Pregnancy explicitly lists ARBs as contraindicated throughout all trimesters and recommends switching women to labetalol, nifedipine, or methyldopa as soon as pregnancy is confirmed or planned.

For an adolescent girl, this means:

• Any girl who is or may become sexually active must use reliable contraception while on losartan.
• Combined hormonal contraceptives (pills, patch, ring) are generally compatible with losartan. Some formulations containing drospirenone have mild potassium-sparing effects; monitoring serum potassium at initiation makes sense in girls also on losartan, since ARBs themselves can cause hyperkalemia.
• If a girl on losartan wants to conceive at any future point (even years away), she needs a transition plan to a pregnancy-safe antihypertensive before stopping contraception.
• Adolescents with Marfan syndrome on losartan require preconception cardiology and maternal-fetal medicine consultation before any pregnancy attempt, given the aortic dissection risk.

Lactation

No published human lactation data exist for losartan. Animal studies show losartan and its active metabolite EXP3174 are present in rat milk. The manufacturer advises against breastfeeding during losartan treatment. For an adolescent who delivers while on losartan (a rare but possible scenario), nifedipine and labetalol have established safety data in lactation and would be appropriate alternatives.

Who This Is Right For (and Who Should Not Take It)

The following framework is developed by the WomanRx clinical team to help clinicians and families think through losartan candidacy for adolescent girls across relevant clinical profiles.

Adolescent Girls Who Are Reasonable Candidates

• A girl aged 12 to 17 with confirmed hypertension (blood pressure above age- and sex-specific 95th percentile on at least three separate readings) who has not responded adequately to lifestyle modification alone.
• A girl with Marfan syndrome, documented aortic root dilation, and cardiology recommendation for ARB therapy.
• A girl with CKD and urine protein-to-creatinine ratio above 0.5 mg/mg who needs nephroprotection alongside blood pressure control.
• A girl with PCOS, established hypertension, and metabolic features where a metabolically neutral antihypertensive is preferred over a beta-blocker.

Adolescent Girls Who Should Not Take Losartan

• Any girl who is pregnant or planning pregnancy in the near term without a concurrent transition plan.
• Girls with bilateral renal artery stenosis (rare in adolescence but possible in fibromuscular dysplasia).
• Girls with severe renal impairment who are already hyperkalemic.
• Girls who are not willing or able to use reliable contraception and are sexually active.
• Girls with a known allergy to losartan or any ARB.

Monitoring and Follow-Up for Adolescent Girls

Monitoring recommendations for adolescent girls on losartan follow adult principles, with attention to the additional variables of growth, cycle status, and evolving contraceptive needs.

At Baseline

Check serum creatinine, estimated GFR, serum potassium, urinalysis with microscopy (if CKD suspected), and a pregnancy test in any sexually active girl. Record height and weight for growth monitoring. Confirm contraceptive status.

At 1 to 4 Weeks After Starting or Dose Change

Recheck blood pressure (in-clinic, not home cuff only), serum potassium, and creatinine. Serum potassium above 5.5 mEq/L warrants dose reduction or temporary hold. Creatinine rise of more than 30% from baseline warrants investigation for volume depletion or renal artery stenosis.

Every 3 to 6 Months

Blood pressure, serum potassium, creatinine, growth parameters. Revisit contraceptive status at every visit, adolescent contraceptive needs change, and a girl who was abstinent at baseline may not be six months later.

Blood Pressure Targets in Adolescent Girls

The 2017 AAP Clinical Practice Guideline targets a blood pressure below the 90th percentile for age, sex, and height in most pediatric patients, or below 130/80 mmHg in adolescents who are 13 or older per the AAP 2017 guideline. Girls with CKD and proteinuria have a tighter target: below the 50th percentile or below 120/80, consistent with the ESCAPE trial protocol.

Drug Interactions Particularly Relevant to Adolescent Girls

Beyond the NSAID interaction noted above, several drug interactions affect girls in this age group more than boys.

Combined hormonal contraceptives and drospirenone: Drospirenone (found in brands like Yaz and Yasmin) has antimineralocorticoid activity and can raise serum potassium by roughly 1 mEq/L. Adding losartan on top of a drospirenone-containing pill increases hyperkalemia risk; potassium should be checked at baseline and at 1 month when combining these.

Fluconazole: A common antifungal used for vaginal yeast infections, fluconazole inhibits CYP2C9 and moderately increases losartan exposure. A short course (single 150 mg dose) is unlikely to cause clinical problems, but repeated courses warrant blood pressure monitoring.

Potassium supplements and salt substitutes: Some teen girls take potassium-containing supplements or electrolyte drinks. Combined with losartan, this can precipitate hyperkalemia.

Lithium: Occasionally prescribed in adolescent girls for bipolar disorder, lithium clearance is reduced by ARBs, risking lithium toxicity.

The Evidence Gap: What We Do Not Know About Losartan in Adolescent Girls

Honest engagement with the evidence gap is a core WomanRx principle.

Virtually all pharmacokinetic data on losartan in pediatrics come from mixed-sex trials. The original pediatric losartan study published in Hypertension (2004) enrolled 177 children aged 6 to 16 and established the weight-based dosing used today, but the publication did not report outcomes broken down by sex. For Marfan syndrome, the COMPARE trial enrolled adults and adolescents together and likewise did not publish sex-stratified pharmacokinetic data.

What we know from adult pharmacokinetic studies is that women achieve approximately 15 to 20% higher AUC for EXP3174 (the active metabolite) than men at comparable weight-adjusted doses. Whether this translates into greater blood-pressure lowering, greater side-effect burden, or better nephroprotection in adolescent girls specifically is unknown. Clinicians extrapolate from adult women when making dosing decisions, and that extrapolation is reasonable but not evidence-based at the adolescent-specific level.

The PCOS application is particularly thin: no published randomized trial has tested losartan specifically in adolescent girls with PCOS and hypertension. Adult data support the use of ARBs in PCOS-related hypertension on mechanistic grounds (RAAS overactivation in insulin-resistant states), but direct evidence in the adolescent female population does not exist as of early 2025.

Talking to Your Daughter's Doctor: Questions Worth Asking

If your daughter (or you, as an adolescent reader) has been prescribed or is being considered for losartan, these questions are clinically relevant.

Is this use on-label or off-label, and what evidence supports it? What blood pressure target are we aiming for, and how will we know if we have reached it? Has a pregnancy test been done before starting? What contraception plan is in place? If my daughter gets a vaginal yeast infection and needs fluconazole, does the dose of losartan need adjusting? What should we do if her potassium comes back elevated?

A good clinical team will answer these without hesitation. If the answers are vague, a second opinion from a pediatric nephrologist or a pediatric cardiologist (for Marfan-related use) is entirely appropriate.